Home>Topics>Stocks>MAP Pharmaceuticals

MAP Pharmaceuticals MAPP

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. UPDATE 1-U.S. contract approved to speed tests of Mapp's Ebola drug

      Headlines

      Tue, 2 Sep 2014

      Sept 2 (Reuters) - The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc.

    2. U.S. govt agency to accelerate development of Mapp's Ebola treatment

      Headlines

      Tue, 2 Sep 2014

      Sept 2 (Reuters) - A U.S. government agency said on Tuesday that it would accelerate the development of an Ebola treatment from Mapp Biopharmaceutical.

    3. Ebola cases accelerating

      Headlines

      Thu, 28 Aug 2014

      NV-INF-1 in Preclinicals; Inovio Pharmaceuticals (NYSEMKT: INO ): SynCon DNA Vaccine in Preclinicals; FujiFilm ( OTC:FUJIF ) ( OTCPK:FUJIY ): Favipiravir in Preclinicals and Mapp Pharmaceuticals: ZMapp in Preclinicals. 1 comment!

    4. Ebola vaccine trials are a top priority for medical authorities

      Headlines

      Thu, 14 Aug 2014

      awaits FDA approval to commence a safety trial for its Ebola vaccine candidate. The trial could start as early as September. Mapp Biopharmaceutical's ZMapp Ebola vaccine was given to the two American medical workers who contracted the disease. Its supply

    5. Tonix May Not Need Final Trial

      Headlines

      Fri, 8 Aug 2014

      noted the similarities between TNX-102 SL and Levadex, Map Pharmaceuticals ' only viable product. We noted that Wells Fargo projected ..... market cap to about 1 X Levadex's projected peak sales. Mapp went from under $2 a share to about $10 per share (we

    6. New Morningstar Analyst Report for Pepco Holdings Inc

      Stock Reports

      Thu, 10 Jul 2014

      address regulatory lag.The cancelation of the $1.2 billion MAPP transmission project, which would have provided a generous 12 ..... Mid-Atlantic Power Pathway project, citing low demand. Absent MAPP , reliability-driven distribution and transmission spending

    7. Allergan Will Control Migraine Portfolio Through Planned MAP Acquisition

      Commentary

      Wed, 23 Jan 2013

      Allergan AGN announced it intends to acquire MAP Pharmaceuticals for approximately $950 million. The news is not particularly surprising because both companies formed a partnership in 2011 for

    8. MAP Pharma shares dive after FDA rejects migraine treatment

      Headlines

      Tue, 27 Mar 2012

      (Reuters) - Shares of MAP Pharmaceuticals Inc fell by a third in premarket trade on Tuesday, after health regulators rejected its orally inhaled treatment for migraine, but analysts remain...

    9. Dropping Coverage of MAP Pharmaceuticals

      Commentary

      Mon, 29 Aug 2011

      We are no longer providing equity research on MAP Pharmaceuticals MAPP . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    10. MAPP Transmission Project Delay In Line With Our Expectations for Pepco

      Commentary

      Fri, 19 Aug 2011

      the projected in-service date for the MAPP transmission project by four to six years ..... be the best-case scenario. Given that MAPP promises 12.8% federally approved returns ..... violations earlier than 2019, making the MAPP transmission project unnecessary at this

    « Prev123Next »
    Content Partners